{"version":"1.0","provider_name":"South Africa Voice","provider_url":"https:\/\/southafricavoice.com","author_name":"South Africa Voice","author_url":"https:\/\/southafricavoice.com\/author\/southafricavoice01\/","title":"Kenya Grants Emergency Use Authorization for the INDICAID(TM) COVID-19 Rapid Antigen Test - South Africa Voice","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"A5T3kVH9CX\"><a href=\"https:\/\/southafricavoice.com\/kenya-grants-emergency-use-authorization-for-the-indicaidtm-covid-19-rapid-antigen-test\/\">Kenya Grants Emergency Use Authorization for the INDICAID(TM) COVID-19 Rapid Antigen Test<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/southafricavoice.com\/kenya-grants-emergency-use-authorization-for-the-indicaidtm-covid-19-rapid-antigen-test\/embed\/#?secret=A5T3kVH9CX\" width=\"600\" height=\"338\" title=\"&#8220;Kenya Grants Emergency Use Authorization for the INDICAID(TM) COVID-19 Rapid Antigen Test&#8221; &#8212; South Africa Voice\" data-secret=\"A5T3kVH9CX\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n<\/script>\n","description":"HONG KONG\u00a0and NAIROBI, Kenya, Aug. 30, 2021 \/PRNewswire\/ \u2014 PHASE Scientific announces that its\u00a0INDICAID\u2122 COVID-19 Rapid Antigen Test (INDICAID\u2122)\u00a0has received Emergency Use Authorization from the Ministry of Health (MOH) of the Republic of Kenya on 17 August 2021. The authorization enables the test to be used in Kenya for the identification of COVID-19 cases, facilitating [\u2026]","thumbnail_url":"https:\/\/ci3.googleusercontent.com\/proxy\/MRVGpAUCgapdvJh1b0W4Uky5aws8FxQMvUqEBKkWPYu4pBvJR8wlRbMIv4TNJkR-OgFkaRdH0iVo58On66NO4ajkUnjzlpuZdQfmEjoWhwWmU7pwuXoGTTTtLMh4=s0-d-e1-ft#https:\/\/mma.prnewswire.com\/media\/1214883\/PHASE_Scientific_Company_Logo.jpg"}